SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Genmab Reports 28.2-Month Median Overall Survival in Phase 2 Trial

Genmab reported a 28.2-month median overall survival with a petosemtamab combination in a Phase 2 trial.

GMAB

Related stories